Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia

ABSTRACT: Introduction: Acute coronary syndrome is one of the most frequent medical emergencies in developing countries.Objective: To determine, from the perspective of the Colombian health system, the cost-effectiveness of ticagrelor compared to clopidogrel for the treatment of patients with acute...

Full description

Autores:
Mejía Mejía, Aurelio
Senior, Juan Manuel
Ceballos González, Mateo
Atehortúa Becerra, Sara Catalina
Toro, Juan Manuel
Saldarriaga, Clara
Mejía, María Elena
Ramírez, Carolina
Tipo de recurso:
Article of journal
Fecha de publicación:
2015
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/31708
Acceso en línea:
https://hdl.handle.net/10495/31708
Palabra clave:
Costos y Análisis de Costo
Costs and Cost Analysis
Economía médica
Economics, Medical
Estudios de Evaluación como Asunto
Evaluation Studies as Topic
Síndrome coronario agudo
Acute Coronary Syndrome
Economía de la salud
Health economics
Rights
openAccess
License
http://creativecommons.org/licenses/by-nc-nd/2.5/co/
id UDEA2_e02e1b717dea8d13efc1ff40b51b296e
oai_identifier_str oai:bibliotecadigital.udea.edu.co:10495/31708
network_acronym_str UDEA2
network_name_str Repositorio UdeA
repository_id_str
dc.title.spa.fl_str_mv Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia
dc.title.alternative.spa.fl_str_mv Análisis de costo-efectividad del ticagrelor en comparación con el clopidogrel para el tratamiento de pacientes con síndrome coronario agudo en Colombia
title Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia
spellingShingle Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia
Costos y Análisis de Costo
Costs and Cost Analysis
Economía médica
Economics, Medical
Estudios de Evaluación como Asunto
Evaluation Studies as Topic
Síndrome coronario agudo
Acute Coronary Syndrome
Economía de la salud
Health economics
title_short Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia
title_full Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia
title_fullStr Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia
title_full_unstemmed Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia
title_sort Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia
dc.creator.fl_str_mv Mejía Mejía, Aurelio
Senior, Juan Manuel
Ceballos González, Mateo
Atehortúa Becerra, Sara Catalina
Toro, Juan Manuel
Saldarriaga, Clara
Mejía, María Elena
Ramírez, Carolina
dc.contributor.author.none.fl_str_mv Mejía Mejía, Aurelio
Senior, Juan Manuel
Ceballos González, Mateo
Atehortúa Becerra, Sara Catalina
Toro, Juan Manuel
Saldarriaga, Clara
Mejía, María Elena
Ramírez, Carolina
dc.subject.decs.none.fl_str_mv Costos y Análisis de Costo
Costs and Cost Analysis
Economía médica
Economics, Medical
Estudios de Evaluación como Asunto
Evaluation Studies as Topic
Síndrome coronario agudo
Acute Coronary Syndrome
topic Costos y Análisis de Costo
Costs and Cost Analysis
Economía médica
Economics, Medical
Estudios de Evaluación como Asunto
Evaluation Studies as Topic
Síndrome coronario agudo
Acute Coronary Syndrome
Economía de la salud
Health economics
dc.subject.unesco.none.fl_str_mv Economía de la salud
Health economics
description ABSTRACT: Introduction: Acute coronary syndrome is one of the most frequent medical emergencies in developing countries.Objective: To determine, from the perspective of the Colombian health system, the cost-effectiveness of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome. Materials and methods: We conducted a cost-effectiveness analysis from the perspective of the Colombian health system comparing ticagrelor and clopidogrel for the treatment of patients with acute coronary syndrome. To estimate the expected costs and outcomes, a Markov model was constructed in which patients could remain stable without experiencing new cardiovascular events, suffer from a new event, or die. For the baseline case, a 10-year time horizon and a discount ratio of 3% for costs and benefits were adopted. The transition probabilities were extracted from the PLATO (Platelet Inhibition and Patient Outcomes) clinical trial. Vital statistics were drawn from the Departmento Administrativo Nacional de Estadística (DANE) and additional information from Colombian patients included in the Access registry. To identify and measure resource use, a standard case was built by consulting guidelines and protocols. Unit costs were obtained from Colombian rate lists. A probabilistic sensitivity analysis was conducted in which costs were represented by a triangular distribution, and the effectiveness through a beta distribution.Results: In the base case, the additional cost per quality-adjusted life-year gained with ticagrelor was COP$ 28,411,503. The results were sensitive to changes in the time horizon and the unit cost of clopidogrel. For a willingness-to-pay equivalent to three times the Colombian per capita gross domestic product, the probability of ticagrelor being cost-effective was 75%. Conclusions: Ticagrelor is a cost-effective strategy for the treatment of patients with acute coronary syndrome in Colombia
publishDate 2015
dc.date.issued.none.fl_str_mv 2015
dc.date.accessioned.none.fl_str_mv 2022-11-02T19:10:15Z
dc.date.available.none.fl_str_mv 2022-11-02T19:10:15Z
dc.type.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.hasversion.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/CJournalArticle
dc.type.local.spa.fl_str_mv Artículo de revista
format http://purl.org/coar/resource_type/c_6501
status_str publishedVersion
dc.identifier.issn.none.fl_str_mv 0120-4157
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/10495/31708
dc.identifier.doi.none.fl_str_mv 10.7705/biomedica.v35i4.2620
dc.identifier.eissn.none.fl_str_mv 2590-7379
identifier_str_mv 0120-4157
10.7705/biomedica.v35i4.2620
2590-7379
url https://hdl.handle.net/10495/31708
dc.language.iso.spa.fl_str_mv eng
language eng
dc.rights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rights.accessrights.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.creativecommons.spa.fl_str_mv https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Instituto Nacional de Salud
dc.publisher.group.spa.fl_str_mv Economía de la Salud
institution Universidad de Antioquia
bitstream.url.fl_str_mv https://bibliotecadigital.udea.edu.co/bitstream/10495/31708/1/MejiaAurelio_2015_CostEffectivenessAnalysis.pdf
https://bibliotecadigital.udea.edu.co/bitstream/10495/31708/2/license_rdf
https://bibliotecadigital.udea.edu.co/bitstream/10495/31708/3/license.txt
bitstream.checksum.fl_str_mv 6fbad113b8b3f89b91412cca34d6b044
b88b088d9957e670ce3b3fbe2eedbc13
8a4605be74aa9ea9d79846c1fba20a33
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad de Antioquia
repository.mail.fl_str_mv andres.perez@udea.edu.co
_version_ 1805390182578388992
spelling Mejía Mejía, AurelioSenior, Juan ManuelCeballos González, MateoAtehortúa Becerra, Sara CatalinaToro, Juan ManuelSaldarriaga, ClaraMejía, María ElenaRamírez, Carolina2022-11-02T19:10:15Z2022-11-02T19:10:15Z20150120-4157https://hdl.handle.net/10495/3170810.7705/biomedica.v35i4.26202590-7379ABSTRACT: Introduction: Acute coronary syndrome is one of the most frequent medical emergencies in developing countries.Objective: To determine, from the perspective of the Colombian health system, the cost-effectiveness of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome. Materials and methods: We conducted a cost-effectiveness analysis from the perspective of the Colombian health system comparing ticagrelor and clopidogrel for the treatment of patients with acute coronary syndrome. To estimate the expected costs and outcomes, a Markov model was constructed in which patients could remain stable without experiencing new cardiovascular events, suffer from a new event, or die. For the baseline case, a 10-year time horizon and a discount ratio of 3% for costs and benefits were adopted. The transition probabilities were extracted from the PLATO (Platelet Inhibition and Patient Outcomes) clinical trial. Vital statistics were drawn from the Departmento Administrativo Nacional de Estadística (DANE) and additional information from Colombian patients included in the Access registry. To identify and measure resource use, a standard case was built by consulting guidelines and protocols. Unit costs were obtained from Colombian rate lists. A probabilistic sensitivity analysis was conducted in which costs were represented by a triangular distribution, and the effectiveness through a beta distribution.Results: In the base case, the additional cost per quality-adjusted life-year gained with ticagrelor was COP$ 28,411,503. The results were sensitive to changes in the time horizon and the unit cost of clopidogrel. For a willingness-to-pay equivalent to three times the Colombian per capita gross domestic product, the probability of ticagrelor being cost-effective was 75%. Conclusions: Ticagrelor is a cost-effective strategy for the treatment of patients with acute coronary syndrome in ColombiaRESUMEN: Introducción. El síndrome coronario agudo es una de las emergencias médicas más frecuentes en los países en desarrollo.Objetivo. Determinar, desde la perspectiva del sistema de salud colombiano, la relación de costo-efectividad del ticagrelor comparado con el clopidogrel para el tratamiento de pacientes con síndrome coronario agudo. Materiales y métodos. Se hizo un análisis de costo-efectividad desde la perspectiva del sistema de salud colombiano, comparando el ticagrelor y el clopidogrel para el tratamiento de pacientes con síndrome coronario agudo. Para estimar los costos y resultados esperados de las dos alternativas, se construyó un modelo de Markov en el cual los pacientes podían permanecer estables sin experimentar nuevos eventos cardiovasculares, sufrir de un nuevo evento coronario o morir. Para el caso de base, se adoptó un horizonte temporal de 10 años y una tasa de descuento de 3 % para los costos y beneficios. Las probabilidades de transición se extrajeron del estudio Platelet Inhibition and Patient Outcomes, PLATO. Las estadísticas vitales se consultaron en informes del Departamento Administrativo Nacional de Estadística (DANE) y los parámetros adicionales del modelo se basaron en la información de los pacientes colombianos incluidos en el registro en Access. Para identificar y medir el uso de recursos, se construyó un caso estándar a partir de guías y protocolos. Los costos unitarios se obtuvieron de manuales tarifarios colombianos. Se hizo un análisis de sensibilidad probabilístico en el que los costos se representaron por una distribución triangular y, las probabilidades de transición, mediante una distribución beta.Resultados. En el caso de base, el costo adicional por años de vida ajustados por calidad ganados con el ticagrelor fue de COP$ 28’411.503. Los resultados fueron sensibles a los cambios en el horizonte temporal y al costo unitario del clopidogrel. Para un umbral de costo-efectividad equivalente a tres veces el producto interno bruto per cápita de Colombia, la probabilidad de que el ticagrelor fuera costo-efectivo fue de 75 %.Conclusiones. El ticagrelor es una estrategia costo-efectiva para el tratamiento de los pacientes con síndrome coronario agudo en Colombia.application/pdfengInstituto Nacional de SaludEconomía de la Saludinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1http://purl.org/redcol/resource_type/CJournalArticleArtículo de revistahttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/http://purl.org/coar/access_right/c_abf2https://creativecommons.org/licenses/by/4.0/Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in ColombiaAnálisis de costo-efectividad del ticagrelor en comparación con el clopidogrel para el tratamiento de pacientes con síndrome coronario agudo en ColombiaCostos y Análisis de CostoCosts and Cost AnalysisEconomía médicaEconomics, MedicalEstudios de Evaluación como AsuntoEvaluation Studies as TopicSíndrome coronario agudoAcute Coronary SyndromeEconomía de la saludHealth economicsRevista Biomédica531540354ORIGINALMejiaAurelio_2015_CostEffectivenessAnalysis.pdfMejiaAurelio_2015_CostEffectivenessAnalysis.pdfArticulo de revistaapplication/pdf217355https://bibliotecadigital.udea.edu.co/bitstream/10495/31708/1/MejiaAurelio_2015_CostEffectivenessAnalysis.pdf6fbad113b8b3f89b91412cca34d6b044MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8823https://bibliotecadigital.udea.edu.co/bitstream/10495/31708/2/license_rdfb88b088d9957e670ce3b3fbe2eedbc13MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstream/10495/31708/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD5310495/31708oai:bibliotecadigital.udea.edu.co:10495/317082022-11-02 14:11:32.992Repositorio Institucional Universidad de Antioquiaandres.perez@udea.edu.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